It was 2020 and Maryland biotech Novavax was thinking big. It had a plan to become a COVID vaccine powerhouse, with enough manufacturing capacity to supply the U.S. all by itself, as its executives ...

On May 10, Novavax announced a co-exclusive licensing agreement with healthcare giant Sanofi. The companies are going to work together on commercializing Novavax's adjuvanted COVID-19 vaccine ...

First, a quick summary of Novavax's story so far. The vaccine maker's shares soared early in the COVID-19 vaccine race, skyrocketing more than 2,000% in 2020 as investors bet on its vaccine candidate.

Jan 20 (Reuters) - Novavax ‌said on Tuesday it signed a licensing ‌agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...

Good morning, and welcome to Novavax' First Quarter 2024 Financial Results and Operational Highlights Conference Call. All lines will be in a listen-only mode. [Operator Instructions]. Please note ...

Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with ...

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Novavax is a biotechnology company specializing in the ...

Vernon Bernardino, an analyst from H.C. Wainwright, maintained the Buy rating on Novavax (NVAX – Research Report). The associated price target remains the same with $19.00. Pick the best stocks and ...

Vaccine maker Novavax inked a three-year supply deal to include its adjuvant in vaccine research backed by an arm of the Bill & Melinda Gates Foundation. As part of the accord, Novavax will provide ...

The vaccine maker Novavax, which has faced several years of dramatic ups and downs around the development of its Covid-19 vaccine, announced Monday that its CEO of more than 11 years, Stanley Erck, ...

Novavax, Inc. (NASDAQ:NVAX) announced results Wednesday of the initial cohort of its COVID-19-Influenza Combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) ...

Novavax is a biotechnology company specializing in the development of recombinant protein-based vaccines, including its COVID-19 shot and the adjuvant Matrix-M, which enhances immune responses. Its ...